CRVS — Corvus Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $895.89m
- $680.66m
U.S. STOCKS ON THE MOVE-Corvus, Dogwood Therapeutics, Uranium Energy
Corvus rises on initiation of mid-stage study for genetic disorder drug
Brief: Corvus Pharmaceuticals starts mid-stage study for its therapy for ALPS, a rare genetic condition
Brief: Corvus Pharmaceuticals Announces Data From Cohort 2 Of Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis
U.S. STOCKS ON THE MOVE-Tesla, Copper miners, Natgas firms
U.S. STOCKS ON THE MOVE-Tesla, Boeing, Gold miners
U.S. RESEARCH ROUNDUP-Biogen, Crown Castle, Eastgroup Properties
U.S. STOCKS ON THE MOVE-Tesla, Gold miners, VICI Properties
H.C. Wainwright starts coverage of Corvus Pharmaceuticals with 'buy' rating
Brief: Corvus Pharmaceuticals Announces Interim Data From Phase 1 Trial Of Soquelitinib For Atopic Dermatitis
Brief: Corvus Pharmaceuticals To Announce Interim Data From Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis On December 18, 2024
Brief: Corvus Pharmaceuticals Announces Publication Of Biochemistry And Preclinical Data
Corvus Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary
Corvus Pharmaceuticals Inc expected to post a loss of 11 cents a share - Earnings Preview
Corvus Pharmaceuticals Inc expected to post a loss of 11 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Freeport-McMoRan, A.O. Smith, Genuine Parts
U.S. STOCKS ON THE MOVE-Lockheed Martin, General Motors, Philip Morris International
U.S. STOCKS ON THE MOVE-3M, Verizon Communications, Kimberly-Clark
Corvus Pharmaceuticals jumps after Mizuho upgrades to 'outperform'